Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis

医学 科克伦图书馆 内科学 不利影响 入射(几何) 荟萃分析 系统回顾 肿瘤科 肺癌 梅德林 政治学 光学 物理 法学
作者
Huijun Xu,Yang Yang,Ying Yan,Mengge Li,Shusheng Wu,Lulu Cao,Wenju Chen,Huiqin Luo,Yifu He
出处
期刊:Cancer Medicine [Wiley]
卷期号:13 (20)
标识
DOI:10.1002/cam4.70324
摘要

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have drastically shifted the current landscape toward a wide variety of malignancies. However, ICIs are interrupted owing immune‐related adverse events (irAEs), therapy completion, and disease progression. The risk–benefit of rechallenged ICIs remains inconclusive. Herein, a systematic review and meta‐analysis were conducted to evaluate the safety and efficacy of ICI rechallenge in the treatment of advanced solid tumor. Methods PubMed, Web of Science, Embase, and Cochrane Library were searched to analyze the efficacy and safety of ICI rechallenge. The study protocol was approved by the PROSPERO International Register of Systematic Reviews (CRD42022372222). The last updated search date was March 2, 2024. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence rates of all‐ and high‐grade irAEs were evaluated. Results A total of 41 retrospective studies comprising 2343 patients were ultimately enrolled for qualitative and quantitative assessments. A total of 1200 (51.2%) individuals were male and the median age was 66 years (range 18–97 years). The majority of the tumors was lung cancer ( n = 898, 38.3%). The occurrence rates of all‐grade and high‐grade (grade 3 or 4) irAEs between initial and readministration ICIs were not significantly different (all‐grade: OR, 0.75, 95% CI: 0.39–1.45, p = 0.40; I 2 = 87%; high‐grade: OR, 0.96, 95% CI: 0.62–1.49, p = 0.87, I 2 = 65%). ICIs restart presented a decreased ORR and DCR compared to initial ICI administration (ORR: OR, 0.36, 95% CI: 0.23–0.56, p < 0.00001; I 2 = 67%; DCR: OR, 0.62, 95% CI: 0.43–0.89, p = 0.010; I 2 = 53%). Seven studies with 513 patients for survival analysis revealed a nonsignificant difference in OS between the ICIs rechallenge and discontinuation cohorts (hazard ratio [HR]: 0.68, 95% confidence interval (CI): 0.35 to 1.35, p = 0.27). Conclusion Rechallenging immunotherapy is feasible, and patients should be carefully evaluated by a multidisciplinary team prior to initial therapy for close monitoring and assessment of the risk–benefit ratio. Therefore, prospective trials are essential to guide clinicians in the decision‐making process. PROSPERO Registration: CRD42022372222.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qian发布了新的文献求助10
刚刚
刚刚
刚刚
1秒前
1秒前
王足各发布了新的文献求助10
2秒前
Owen应助Ebony采纳,获得10
3秒前
4秒前
量子星尘发布了新的文献求助10
6秒前
stars发布了新的文献求助10
6秒前
6秒前
6秒前
qian完成签到,获得积分10
7秒前
7秒前
mealies发布了新的文献求助10
7秒前
斯文败类应助如此采纳,获得10
8秒前
8秒前
9秒前
呈沉发布了新的文献求助10
9秒前
11秒前
M旭旭发布了新的文献求助10
12秒前
科研通AI2S应助scsc采纳,获得10
12秒前
13秒前
清新的夏烟完成签到,获得积分10
13秒前
飞云完成签到,获得积分10
13秒前
椰青冰萃发布了新的文献求助30
14秒前
14秒前
Owen应助野性的博涛采纳,获得10
15秒前
马康辉发布了新的文献求助10
15秒前
15秒前
18秒前
111应助快乐小汉堡采纳,获得10
18秒前
执念完成签到 ,获得积分10
18秒前
慕青应助Guochunbao采纳,获得10
18秒前
M旭旭完成签到,获得积分10
18秒前
19秒前
19秒前
lbx发布了新的文献求助10
19秒前
20秒前
20秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 310
The Moiseyev Dance Company Tours America: "Wholesome" Comfort during a Cold War 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3979946
求助须知:如何正确求助?哪些是违规求助? 3524093
关于积分的说明 11219832
捐赠科研通 3261529
什么是DOI,文献DOI怎么找? 1800686
邀请新用户注册赠送积分活动 879263
科研通“疑难数据库(出版商)”最低求助积分说明 807226